Today’s Research Reports on Aptose Biosciences, Fennec Pharmaceuticals, Valeant Pharmaceuticals and BELLUS Health

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/news/?ticker=VRX.TO

BELLUS Health Inc.
https://rdinvesting.com/news/?ticker=BLU.TO

Aptose Biosciences’ stock moved 2.79% higher Wednesday, to close the day at $4.79. The stock recorded a trading volume of 58,385 shares, which was above its three months average volume of 36,875 shares. In the last year, Aptose Biosciences’ shares have traded in a range of 1.39 – 5.18. The share price has gained 244.60% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.36 is greater than its 200-day moving average of $3.67. Shares of Aptose Biosciences have gained approximately 72.30 percent year-to-date.

Access RDI’s Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

On Wednesday, shares of Fennec Pharmaceuticals recorded a trading volume of 10,045 shares, which was above the three months average volume of 3,521 shares. The stock ended the day 2.83% higher at 14.51. The share price has gained 167.71% from its 52 week low with a 52 week trading range of 5.42 – 18.86. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $15.40 is greater than its 200-day moving average of $13.26. Shares of Fennec Pharmaceuticals have gained approximately 16.17 percent year-to-date.

Access RDI’s Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

Valeant Pharmaceuticals International’s stock jumped 7.52% Wednesday, to close the day at $32.90. The stock recorded a trading volume of 1,927,833 shares, which was above its three months average volume of 1,089,321 shares. In the last year, Valeant Pharmaceuticals International’s shares have traded in a range of 14.01 – 32.95. The share price has gained 134.83% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $25.69 is greater than its 200-day moving average of $23.98. Shares of the company are trading at a Price to Earnings ratio of 4.82. Shares of Valeant Pharmaceuticals have gained approximately 25.57 percent year-to-date.

Access RDI’s Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX.TO

On Wednesday, shares of BELLUS Health recorded a trading volume of 17,957 shares, which was below the three months average volume of 101,532 shares. The stock ended the day flat at 0.58. The share price has gained 81.25% from its 52 week low with a 52 week trading range of 0.32 – 0.62. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.53 is greater than its 200-day moving average of $0.45. Shares of BELLUS Health have gained approximately 56.76 percent year-to-date.

Access RDI’s BELLUS Health Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLU.TO

Our Actionable Research on Aptose Biosciences Inc. (TSX:APS.TO), Fennec Pharmaceuticals Inc. (TSX:FRX.TO), Valeant Pharmaceuticals International, Inc. (TSX:VRX.TO) and BELLUS Health Inc. (TSX:BLU.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 502001